124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Zou, Peng ^a,b   Povoski, Stephen P ^c   Hall, Nathan C ^a   Carlton, Michelle M ^a   Hinkle, George H ^a   Xu, Ronald X ^d   Mojzisik, Cathy M ^a   Johnson, Morgan A ^a   Knopp, Michael V ^a   Martin Jr, Edward W ^c   Sun, Duxin ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Ohio State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN; GLYCOPROTEIN TAG72; IODINE 124; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUCC49DELTACH2 60 63; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B72.3 ANTIBODY; CANCER ANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 72; TUMOR-ASSOCIATED ANTIGEN 72;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLADDER; BROWN ADIPOSE TISSUE; CANCER DIAGNOSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; HARDER GLAND; HEART; ISOTOPE LABELING; KIDNEY; MOUSE; NECK; NONHUMAN; PERITONEAL CAVITY; POSITRON EMISSION TOMOGRAPHY; SYSTEMIC CIRCULATION; TUMOR XENOGRAFT; VITREOUS BODY; ADENOCARCINOMA; ANIMAL; COLON TUMOR; DRUG SCREENING; HUMAN; IMMUNOLOGY; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLYCOPROTEINS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955200847     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-65     Document Type: Article

References (85)

1. Brownell GL. A history of positron imaging. 1999, http://www.mit.edu/~glb/
2. Chesler DA. Three-dimensional activity distribution from multiple positron scintigraphs. J Nucl Med 1971, 12:347-348.
3. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 1975, 114:89-98.
4. Hoffmann EJ, Phelps ME, Mullani NA, Higgins CS, Ter-Pogossian MM. Design and performance characteristics of a whole-body positron transaxial tomograph. J Nucl Med 1976, 17:493-502.
5. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities?. Semin Nucl Med 1997, 27:94-106. 10.1016/S0001-2998(97)80042-6, 9144854.
6. Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest 2004, 51:14-19. 10.2152/jmi.51.14, 15000251.
7. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006, 11:286-296. 10.1007/s10147-006-0595-0, 16937302.
8. Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin Transl Oncol 2007, 9:494-505. 10.1007/s12094-007-0093-5, 17720652.
9. Otsuka H, Morita N, Yamashita K, Nishitani H. FDG-PET/CT for cancer management. J Med Invest 2007, 54:195-199. 10.2152/jmi.54.195, 17878667.
10. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009, 70:382-92. 10.1016/j.ejrad.2009.03.051, 19406595.
11. Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ. Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging 2009, 53:224-244.
12. Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 2008, 52:50-65.
13. Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009, 50(Suppl 1):106S-121S. 10.2967/jnumed.108.057281, 19380404.
14. Murphy PS, Bergström M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr Pharm Des 2009, 15:957-965. 10.2174/138161209787581977, 19275660.
15. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009, 53:158-166.
16. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007, 37:400-419. 10.1053/j.semnuclmed.2007.08.004, 17920348.
17. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998, 25:317-322. 10.1016/S0969-8051(97)00226-6, 9639291.
18. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 4:1334-1336. 10.1038/3337, 9809561.
19. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S125-S134.
20. Lim HS, Yoon W, Chung TW, Kim JK, Park JG, Kang HK, Bom HS, Yoon JH. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007, 27(Suppl 1):S197-S213. 10.1148/rg.27si075507, 18180227.
21. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007, 37:206-222. 10.1053/j.semnuclmed.2007.01.001, 17418153.
22. Sun D, Bloomston M, Hinkle G, Al-Saif OH, Hall NC, Povoski SP, Arnold MW, Martin EW. Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. J Surg Oncol 2007, 96:297-308. 10.1002/jso.20869, 17726663.
23. Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 2008, 46:225-241. 10.1016/j.rcl.2008.04.002, 18619378.
24. Povoski SP, Neff RL, Mojzisik CM, O'Malley DM, Hinkle GH, Hall NC, Murrey DA, Knopp MV, Martin EW. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 2009, 7:11. 10.1186/1477-7819-7-11, 2653072, 19173715.
25. Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 1985, 45:833-840.
26. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986, 46:850-857.
27. Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988, 48:6811-6818.
28. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976, 12:180-191. 10.1007/BF02796440, 1262041.
29. Tom BH, Rutzky LP, Oyasu R, Tomita JT, Goldenberg DM, Kahan BD. Human colon adenocarcinoma cells. II. Tumorigenic and organoid expression in vivo and in vitro. J Natl Cancer Inst 1977, 58:1507-1512.
30. Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984, 44:5744-5749.
31. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988, 48:4597-4603.
32. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, Tuttle SE, Hinkle GH, Rousseau M, Schlom J, Colcher D, Thurston MO, Nieroda C, Sardi A, Farrar WB, Minton JP, Martin EW. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 1987, 30:761-764. 10.1007/BF02554623, 3652889.
33. Tuttle SE, Jewell SD, Mojzisik CM, Hinkle GH, Colcher D, Schlom J, Martin EW. Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization. Int J Cancer 1988, 42:352-358. 10.1002/ijc.2910420308, 3417363.
34. Martin EW, Mojzisik CM, Hinkle GH, Sampsel J, Siddiqi M, Tuttle SE, Sickle-Santanello B, Colcher D, Thurston MO, Bell J, Farrar WB, Schlom J. Radioimmunoguided surgery using monoclonal antibody. Am J Surg 1988, 156:386-392. 10.1016/S0002-9610(88)80193-4, 3189709.
35. Nieroda CA, Mojzisik C, Sardi A, Farrar WB, Hinkle G, Siddiqi MA, Ferrara PJ, James A, Schlom J, Thurston MO, Martin EW. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg Gynecol Obstet 1989, 169:35-40.
36. Sardi A, Siddiqi MA, Hinkle GH, Rousseau M, Gersman M, Hill T, Olsen J, Tuttle SE, Young D, Houchens D, Thurston M, Martin EW. Localization by hand-held gamma probe of tumor labeled with antibody "cocktail". J Surg Res 1989, 47:227-234. 10.1016/0022-4804(89)90112-1, 2770279.
37. Nieroda CA, Mojzisik C, Sardi A, Ferrara P, Hinkle G, Thurston MO, Martin EW. Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev 1990, 14:651-656.
38. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991, 15:225-229.
39. Cohen AM, Martin EW, Lavery I, Daly J, Sardi A, Aitken D, Bland K, Mojzisik C, Hinkle G. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991, 126:349-352.
40. Martin EW, Carey LC. Second-look surgery for colorectal cancer. The second time around. Ann Surg 1991, 214:321-325. discussion 326-327, 10.1097/00000658-199109000-00014, 1358655, 1929612.
41. Arnold MW, Schneebaum S, Berens A, Petty L, Mojzisik C, Hinkle G, Martin EW. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992, 216:627-632. 10.1097/00000658-199212000-00003, 1242708, 1466615.
42. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992, 112:624-629. discussion 629-630.
43. Schneebaum S, Arnold MW, Houchens DP, Greenson JK, Cote RJ, Hitchcock CL, Young DC, Mojzisik CM, Martin EW. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995, 75:2809-2817. 10.1002/1097-0142(19950615)75:12<2809::AID-CNCR2820751205>3.0.CO;2-0, 7773931.
44. Bertsch DJ, Burak WE, Young DC, Arnold MW, Martin EW. Radioimmunoguided surgery improves survival for patients recurrent colorectal cancer. Surgery 1995, 118:634-638. discussion 638-639, 10.1016/S0039-6060(05)80029-7, 7570316.
45. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW. Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg 1995, 170:315-318. 10.1016/S0002-9610(99)80295-5, 7573720.
46. Cote RJ, Houchens DP, Hitchcock CL, Saad AD, Nines RG, Greenson JK, Schneebaum S, Arnold MW, Martin EW. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer 1996, 77:613-620. 10.1002/(SICI)1097-0142(19960215)77:4<613::AID-CNCR5>3.0.CO;2-H, 8616751.
47. Arnold MW, Hitchcock CL, Young DC, Burak WE, Bertsch DJ, Martin EW. Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Dis Colon Rectum 1996, 39:509-513. 10.1007/BF02058702, 8620799.
48. Bertsch DJ, Burak WE, Young DC, Arnold MW, Martin EW. Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996, 3:310-316. 10.1007/BF02306288, 8726188.
49. Martinez DA, Barbera-Guillem E, LaValle GJ, Martin EW. Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 1997, 4:505-516.
50. Martin EW, Thurston MO. Intraoperative radioimmunodetection. Semin Surg Oncol 1998, 15:205-208. 10.1002/(SICI)1098-2388(199812)15:4<205::AID-SSU2>3.0.CO;2-S, 9829371.
51. Bakalakos EA, Young DC, Martin EW. Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 1998, 5:590-594. 10.1007/BF02303827, 9831106.
52. Arnold MW, Young DM, Hitchcock CL, Barberá-Guillem E, Nieroda C, Martin EW. Staging of colorectal cancer: biology vs. morphology. Dis Colon Rectum 1998, 41:1482-1487. 10.1007/BF02237292, 9860326.
53. Schneebaum S, Troitsa A, Avital S, Haddad R, Kashtan H, Gitstein G, Baratz M, Brazovsky E, Papo J, Skornick Y. Identification of lymph node metastases in recurrent colorectal cancer. Recent Results Cancer Res 2000, 157:281-292.
54. Avital S, Haddad R, Troitsa A, Kashtan H, Brazovsky E, Gitstein G, Skornick Y, Schneebaum S. Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation. Cancer 2000, 89:1692-1698. 10.1002/1097-0142(20001015)89:8<1692::AID-CNCR7>3.0.CO;2-2, 11042562.
55. Schneebaum S, Troitsa A, Haddad R, Avital S, Kashtan H, Baratz M, Brazovsky E, Papo J, Skornick Y. Immunoguided lymph node dissection in colorectal cancer: a new challenge?. World J Surg 2001, 25:1495-1498. discussion 1499.
56. Haddad R, Avital S, Troitsa A, Chen J, Baratz M, Brazovsky E, Gitstein G, Kashtan H, Skornick Y, Schneebaum S. Benefits of radioimmunoguided surgery for pelvic recurrence. Eur J Surg Oncol 2001, 27:298-301. 10.1053/ejso.2000.1108, 11373109.
57. Agnese DM, Abdessalam SF, Burak WE, Arnold MW, Soble D, Hinkle GH, Young D, Kazaeli MB, Martin EW. Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔCH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol 2004, 11:197-202. 10.1245/ASO.2004.05.010, 14761924.
58. Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005, 20:16-26. 10.1089/cbr.2005.20.16, 15778575.
59. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Sun D. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 2007, 47:227-237. 10.1177/0091270006293758, 17244774.
60. Calvo B, Kashmiri SV, Hutzell P, Hand PH, Slavin-Chiorini DC, Schlom J, Zaremba S. Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody. Cancer Biother 1993, 8:95-109.
61. Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993, 53:97-103. 10.1002/ijc.2910530119, 8416208.
62. Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, Horan Hand P. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995, 55(23 Suppl):5957s-5967s.
63. Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997, 12:305-316. 10.1089/cbr.1997.12.305, 10851481.
64. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, Robeson WR, Larson SM. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996, 37:1557-1562.
65. Hinkle GH, Nabi HA, Miller EA, Schlanger LE, Houchens DP, Thurston MO, Aitken DR, Mojzisik CM, Olsen JO, Tuttle SE, Hansen HJ, Haagensen DE, Martin EW. Radioimmunodetection of implanted tumors with gamma probe. NCI Monogr 1987, 3:83-87.
66. Unak T, Akgün Z, Yildirim Y, Duman Y, Erenel G. Self-radioiodination of iodogen. Appl Radiat Isot 2001, 54:749-752. 10.1016/S0969-8043(00)00337-7, 11258523.
67. Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW, Subramaniam V, Xu R, Sun D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 2009, 6:428-440. 10.1021/mp9000052, 19718796.
68. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066.
69. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007, 48:602-607. 10.2967/jnumed.106.036608, 17401098.
70. Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008, 8:16. 10.1186/1471-2342-8-16, 2575188, 18925932.
71. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987, 47:4218-4224.
72. Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker P, Larson SM. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiol Suppl 1990, 374:123-128.
73. Hall NC, Zhang J, Povoski SP, Martin EW, Knopp MV. New developments in imaging and functional biomarker technology for the assessment and management of cancer patients. Expert Rev Med Devices 2009, 6:347-351. 10.1586/erd.09.21, 19572788.
74. Pochin EE, Barnaby CF. The effect of pharmacological doses of non-radioactive iodide on the course of radio-iodine uptake by the thyroid. Health Phys 1962, 7:125-126. 10.1097/00004032-196201000-00001, 14487291.
75. Blum M, Eisenbud M. Reduction of thyroid irradiation from 131-I by potassium iodide. JAMA 1967, 200:1036-1040. 10.1001/jama.200.12.1036, 5337789.
76. Meck RA, Chen MS, Kenny PJ. Criteria for the administration of KI for thyroid blocking of radioiodine. Health Phys 1985, 48:141-157. 10.1097/00004032-198502000-00001, 3882630.
77. Abdel-Nabi H, Waldman WJ, Hinkle GH, Miller EA, Trembath L, Olsen JO, Martin EW. Comparison of L-thyroxine and a saturated solution of potassium iodide in preventing damage to the thyroid following iodine-131-labeled antibody injection. NCI Monogr 1987, 3:63-66.
78. Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Jurisson SS, Lewis MR. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem 2006, 17:485-492. 10.1021/bc0502356, 16536481.
79. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993, 53:3776-3783.
80. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008, 49:938-955. 10.2967/jnumed.108.051276, 18483101.
81. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008, 53:R1-R39. 10.1088/0031-9155/53/4/R01, 18263942.
82. Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008, 185(Pt 1):109-132. full_text, 18626801.
83. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med 2009, 39:348-353. 10.1053/j.semnuclmed.2009.03.001, 19646559.
84. Lee KH, Ko BH, Paik JY, Jung KH, Choe YS, Choi Y, Kim BT. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 2005, 46:1531-1536.
85. Woo SK, Lee TS, Kim KM, Kim JY, Jung JH, Kang JH, Cheon GJ, Choi CW, Lim SM. Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET. Nucl Med Biol 2008, 35:143-150. 10.1016/j.nucmedbio.2007.10.003, 18158953.